ADPT
Not exactly a vote of confidence
Adaptive Biotechnologies’ president and COO sold 57,180 shares across multiple days ending April 16, and the haul came out to roughly $826,000. For a company that lives and dies on investor faith in its story, insider sales can feel a little like seeing the chef leave the restaurant mid-dinner service.
Should you panic?
Not necessarily. Executives sell for all kinds of reasons — taxes, diversification, life stuff, or just wanting fewer eggs in one basket. But when a top insider trims a meaningful chunk, it can still make investors wonder whether the stock has more near-term upside than the person closest to the business is willing to keep riding.
Why traders will notice
This is the kind of news that doesn’t change the company’s science overnight, but it can change the mood around the stock. ADPT investors may watch whether other insiders follow suit or whether management later pairs this with upbeat operating commentary that softens the optics.
Big picture: insider sales are rarely the whole story, but they’re one of those little tells Wall Street loves to obsess over.